The burden is particularly high in urban areas, where the prevalence reaches 15.2 percent compared to just 2.0 percent in ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

In India, the prevalence of chronic kidney disease (CKD) has reached epidemic proportions, with population-based studies ...

In its early stages, kidney disease may not cause any symptoms or signs. However, as it progresses, it can cause symptoms such as itchy skin, pruritus, and a rash. Around 35.5 million adults in ...

The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Using a handheld dynamometer to assess hip flexion and abduction strength during dialysis was reliable and safe, researchers ...

Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...